Shares of Johnson & Johnson are up approximately $5 per share or over 3% in after-hours trading on Tuesday to $164 per share after announcing a nearly $9B settlement over claims that its talcum powder causes cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson Offers to Pay $8.9B in Bankruptcy Filing
- J&J’s Janssen discontinues RSV adult vaccine program
- Johnson & Johnson assumed with a Neutral at UBS
- STAAR Surgical names Warren Foust COO, Magda Michna, as chief of medical affairs
- Johnson & Johnson initiated with a Neutral at UBS
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue